METAMIZOLE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H16N3O4S.Na
Molecular Weight	333.339
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2

InChI

InChIKey=DJGAAPFSPWAYTJ-UHFFFAOYSA-M

InChI=1S/C13H17N3O4S.Na/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11;/h4-8H,9H2,1-3H3,(H,18,19,20);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H16N3O4S
Molecular Weight	310.349
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.un.org/esa/coordination/CL12.pdf

Dipyrone, also known as Metamizole (INN), is an ampyrone sulfonate analgesic, antispasmodic and antipyretic. It was withdrawn from US market in 1977 on the basis of reports of agranulocytosis. Depyrone is still used to treat severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. Mechanism of action of dipyrone is complex. It is believed that dipyrone exerts its action by inhibiting COX-3, and activates opioid and cannabioid systems either itself, or by products of its metabolic degradation.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 1 30 Target ID: P23219\|\|\|Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: http://www.actavis.bg/nr/rdonlyres/27cd192d-b3cd-4e81-a7a3-fa80f56bf148/0/neuragin_eng.pdf	Primary		Approved 8429	NEURALGIN Approved Use Severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states.
Hyperthermia 5 Sources: http://www.pharmaline.co.il/images/newsletterregistration/teva/07102011/optalgininjdr.pdf	Primary		Approved 8429	OPTALGIN Approved Use Optalgin Injection, by intramuscular administration, is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.

PubMed

Title	Date	PubMed
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.	1984	6430038
Modifying potential of thirty-one chemicals on the short-term development of gamma-glutamyl transpeptidase-positive foci in diethylnitrosamine-initiated rat liver.	1984 Oct	6150874
Mode of analgesic action of dipyrone: direct antagonism of inflammatory hyperalgesia.	1985 Aug 27	2998815
Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships.	1987 Nov	3425858
Octreotide dependency and headache: a case report.	1994 Aug	7954762
Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia.	1996 Jun	8814464
Doctor, there's a fly in my soup! Angiotensin-converting enzyme inhibitors, endogenous opioids and visual hallucinations.	2001 Dec	11794927
Metamizol potentiates morphine antinociception but not constipation after chronic treatment.	2002 Apr 26	12063090

Patents

Sample Use Guides

In Vivo Use Guide

Dipyrone was administered orally, as subcutaneous and intramuscular injections (daily dose 0.25-1 g as 50% solution), or by intravenous injection.

Route of Administration: Other

In Vitro Use Guide

Cyclooxygenase activity was measured by the formation of PGE2 after exposure to exogenous 30 μM acid for 10 min. Dipyrone inhibited COX-1 with IC50 350 uM, and COX-3 with IC50 of 52 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:53:20 UTC 2023` Edited by `admin` on `Fri Dec 15 16:53:20 UTC 2023`
Record UNII	VSU62Z74ON
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METAMIZOLE SODIUM

Official Name

English

SODIUM 1-PHENYL-2,3-DIMETHYL-4-METHYLAMINOPYRAZOLON-N-METHANESULFONATE

Common Name

English

NORAMIDOPYRINE METHANESULFONATE SODIUM

Common Name

English

METAMIZOLE SODIUM [EP IMPURITY]

Common Name

English

SODIUM 1-PHENYL-2,3-DIMETHYL-4-METHYLAMINOPYRAZOLON-N-METHANESULPHONATE

Common Name

English

METAMIZOLUM NATRICUM ANHYDRICUM

Common Name

English

METHANESULFONIC ACID, (ANTIPYRINYLMETHYLAMINO)-, SODIUM SALT

Common Name

English

metamizole sodium [INN]

Common Name

English

NORAMIDOPYRINE METHANESULPHONATE SODIUM

Common Name

English

Metamizole sodium [WHO-DD]

Common Name

English

METAMIZOLE SODIUM (ANHYDROUS)

Common Name

English

DIPYRONE ANHYDROUS

Common Name

English

Classification Tree Code System Code

WHO-ATC

N02BB52